Cargando…

Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma

INTRODUCTION: Real-world data on recurrence and economic burden in patients with resected early-stage melanoma are limited. The objective of this study was to assess real-world recurrence rates, risk factors for recurrence, and costs of recurrence in patients with resected stage IIB, IIC, or IIIA me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Sekwon, Poretta, Tayla, Bhagnani, Tarun, Harshaw, Qing, Burke, Matthew, Rao, Sumati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477064/ https://www.ncbi.nlm.nih.gov/pubmed/32548707 http://dx.doi.org/10.1007/s13555-020-00404-9

Ejemplares similares

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior
por: Beisel, Cassie, et al.
Publicado: (2022)

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
por: Lee, Jay M., et al.
Publicado: (2023)

Economic Burden of Heart Failure in Asian Countries Based on Real-world Data
por: Chung, Hyemoon, et al.
Publicado: (2021)

The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis
por: Barer, Yael, et al.
Publicado: (2022)

Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy
por: Antonini, Giovanni, et al.
Publicado: (2023)

Real-world treatment patterns and economic burden of post-cataract macular edema
por: Ahmadyar, Gina, et al.
Publicado: (2023)

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings
por: Joseph, Richard W., et al.
Publicado: (2020)

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
por: De Franceschi, Lucia, et al.
Publicado: (2022)

Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe
por: Burke, Tom, et al.
Publicado: (2021)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
por: Huang, Qing, et al.
Publicado: (2022)

Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
por: Soliman, Ahmed M., et al.
Publicado: (2018)

Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany
por: Jud, Sebastian M., et al.
Publicado: (2020)

P1158: REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF PATIENTS WITH MARGINAL ZONE LYMPHOMA
por: Yang, K., et al.
Publicado: (2022)

Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
por: Perrone, Valentina, et al.
Publicado: (2023)

Prevalence and economic burden of dementia in the Arab world
por: Qassem, Tarik, et al.
Publicado: (2023)

Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer
por: West, Howard, et al.
Publicado: (2023)

Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
por: Bonine, Nicole G, et al.
Publicado: (2017)

False positive rapid antigen tests for SARS-CoV-2 in the real-world and their economic burden
por: Kretschmer, Andreas, et al.
Publicado: (2022)

Contemporary economic burden in a real‐world heart failure population with Commercial and Medicare supplemental plans
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Estimating the economic burden of osteoporotic fractures in a multinational study: a real-world data perspective
por: Moayyeri, A., et al.
Publicado: (2023)

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
por: Slingluff, Craig L, et al.
Publicado: (2021)

Economic burden of osteoporosis in the world: A systematic review
por: Rashki Kemmak, Asma, et al.
Publicado: (2020)

Clinical predictors of survival in real world practice in stage IV melanoma
por: Hu, Hsien‐Pang, et al.
Publicado: (2022)

Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma
por: Liu, Jun S., et al.
Publicado: (2016)

Real world economic outlook : the legacy of globalization : debt and deflation /
Publicado: (2003)

Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data
por: Kwon, Sun-Hong, et al.
Publicado: (2022)

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
por: Rodríguez-Nieto, Maria Jesus, et al.
Publicado: (2023)

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis
por: Feuerstadt, Paul, et al.
Publicado: (2022)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis
por: Hoffmann, Michèle, et al.
Publicado: (2022)

Economic burden of toxicities associated with treating metastatic melanoma in eight countries
por: Wehler, Elizabeth, et al.
Publicado: (2015)

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States
por: Martin, Amber, et al.
Publicado: (2022)

The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
por: Breccia, Massimo, et al.
Publicado: (2022)

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA
por: Barzi, Afsaneh, et al.
Publicado: (2023)

Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report
por: Sadaat, Masood, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cdcke2nqtde9s8rjjsnhltv00k